telmisartan + s-amlodipine + rosuvastatin

Telmisartan + s-amlodipine + rosuvastatin is a fixed-dose combination of three small molecule drugs used primarily for the management of patients with both hypertension and dyslipidemia. Telmisartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, leading to vasodilation. S-amlodipine is a calcium channel blocker (CCB) that inhibits calcium influx into vascular smooth muscle and cardiac muscle, resulting in relaxation of blood vessels and further reduction in blood pressure. Rosuvastatin is a statin that selectively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis; this leads to decreased cholesterol production and increased clearance of low-density lipoprotein cholesterol (LDL-C). The triple combination targets two major cardiovascular risk factors—high blood pressure and high cholesterol—offering improved efficacy over dual or monotherapy regimens for patients at high risk for cardiovascular events[1][2][4][6].

Other names

telmisartan + s-amlodipine + rosuvastatinTAR (triple therapy)telmisartan/amlodipine/rosuvastatintelmisartan plus amlodipine plus rosuvastatin